Simplex Trading
VTGN icon

Simplex Trading’s VistaGen Therapeutics VTGN Stock Holding History

Simplex Trading’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.09K Sell
8,900
-169,800
-95% -$103K ﹤0.01% 7885
2025
Q4 		$118K Buy
178,700
+131,200
+276% +$474K ﹤0.01% 4820
2025
Q3 		$168K Buy
+47,500
New +$142K ﹤0.01% 5148
2025
Q1 		– Sell
-3,500
Closed -$10K – 9800
2024
Q4 		$10K Sell
3,500
-34,500
-91% -$97.1K ﹤0.01% 7223
2024
Q3 		$114K Sell
38,000
-31,300
-45% -$107K ﹤0.01% 5102
2024
Q2 		$241K Sell
69,300
-34,000
-33% -$147K ﹤0.01% 4479
2024
Q1 		$545K Buy
103,300
+98,900
+2,248% +$476K ﹤0.01% 3772
2023
Q4 		$22K Sell
4,400
-4,100
-48% -$15.5K ﹤0.01% 6859
2023
Q3 		$44K Buy
+8,500
New +$37.7K ﹤0.01% 5931
2023
Q1 		– Sell
-460
Closed -$1K – 10238
2022
Q4 		$1K Sell
460
-1,467
-76% -$5.52K ﹤0.01% 8953
2022
Q3 		$8K Buy
1,927
+977
+103% +$9.68K ﹤0.01% 8454
2022
Q2 		$25K Buy
950
+217
+30% +$7.66K ﹤0.01% 7358
2022
Q1 		$27K Sell
733
-144
-16% -$6.28K ﹤0.01% 7912
2021
Q4 		$51K Buy
+877
New +$57.1K ﹤0.01% 7241

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Simplex Trading's VTGN Position: Q1 2026 in Review

Simplex Trading opened a new position in VistaGen Therapeutics (VTGN) in Q1 2026: 89,649 shares worth $51.3K. The stake represents ﹤0.01% of the portfolio and ranks #5854 among its holdings. This is a return to the name: Simplex Trading previously reported a position in VTGN as recently as Q2 2025.

Simplex Trading first reported a position in VTGN in Q2 2022 and has held it in 13 quarters since. The position peaked at $69K in Q3 2024. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Simplex Trading held 89,649 shares of VistaGen Therapeutics worth $51.3K as of Q1 2026.
  • VistaGen Therapeutics was a new Simplex Trading position in Q1 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #5854 holding.
  • Simplex Trading first reported a position in VistaGen Therapeutics in Q2 2022 and has held it in 13 quarters since.
  • Simplex Trading's VistaGen Therapeutics position peaked at $69K in Q3 2024.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.